Literature DB >> 3980990

Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes.

G Hale, M Clark, H Waldmann.   

Abstract

The ability of rat monoclonal antibodies to promote antibody-dependent cell-mediated cytotoxicity with human effector cells was tested by using a variety of antibodies against different human and mouse leukocyte antigens. It was found that only IgG2b antibodies were effective. This isotype has already been shown to be efficient in fixing human complement, which suggests that among rat monoclonal antibodies, the IgG2b subclass might be a good choice for attempts at serotherapy. Further studies with other antibody-mediated effector mechanisms as well as suitable clinical trials are merited.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3980990

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

Authors:  M A Ghetie; E M Podar; A Ilgen; B E Gordon; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 3.  Development of antibody surrogates for the treatment of cancers and autoimmune disease.

Authors:  Thomas Kodadek
Journal:  Curr Opin Chem Biol       Date:  2010-07-31       Impact factor: 8.822

4.  Characterization of monoclonal antibodies specific for alpha- and beta-chains of sheep MHC class II.

Authors:  B M Dutia; J Hopkins; M P Allington; R Bujdoso; I McConnell
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

5.  Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation.

Authors:  B E Shaw; F Lee; S Krishnamurthy; J L Byrne; C Seedhouse; N P Mayor; H Maldonado-Torres; A Saudemont; S G E Marsh; J A Madrigal; N H Russell
Journal:  Bone Marrow Transplant       Date:  2014-10-27       Impact factor: 5.483

6.  A receptor for monomeric IgG2b on rat macrophages.

Authors:  S Denham; R Barfoot; E Jackson
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

7.  Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.

Authors:  Andrew Mone; Shannon Puhalla; Susan Whitman; Robert A Baiocchi; Julio Cruz; Tamara Vukosavljevic; Amy Banks; Charles F Eisenbeis; John C Byrd; Michael A Caligiuri; Pierluigi Porcu
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

8.  Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.

Authors:  Ryan P Murelli; Andrew X Zhang; Julien Michel; William L Jorgensen; David A Spiegel
Journal:  J Am Chem Soc       Date:  2009-12-02       Impact factor: 15.419

Review 9.  Recent trends in targeted anticancer prodrug and conjugate design.

Authors:  Yashveer Singh; Matthew Palombo; Patrick J Sinko
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

10.  BB-DR/Edinburgh: a lymphopenic, non-diabetic subline of BB rats.

Authors:  S Joseph; A G Diamond; W Smith; J D Baird; G W Butcher
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.